{‘She has zero qualifications’: the US healthcare community prepares for Dr. Høeg's tenure at the FDA.

As the US continues making historic adjustments to its vaccine guidelines, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by expressing skepticism about Covid shots in the pandemic and has focused upon potential deaths following COVID-19 vaccination in her short position at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Immunization Schedule

Agency leaders planned to announce radical revisions to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s immunization schedule, sources say – a major change that would put the US out of alignment with much of the global community with little proof for public health gain. This reveal has been postponed until the coming year.

In place of Vinay Prasad, Høeg is scheduled to speak at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this calendar year.

Consolidating Power at the Agency

This interim role may indicate a strengthened alliance between the pharmaceutical and biologics centers as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a increased emphasis upon dismantling previously authorized immunizations at the FDA.

Høeg has repeatedly called for halting some pediatric immunization guidelines in the US in order to be more like the Danish model, a society with nationalized medicine and a number of inhabitants roughly the population of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on vaccination policy – typically the purview of Dr. Prasad, director of the FDA’s CBER – rather than medication approval.

Questions Over Expertise

Høeg has no obvious experience in drug development, regulation or leadership, which has been customary for past leaders of the biologics center. She has served at the FDA as a top consultant to the FDA chief and CBER since March.

“It seems she lacks to have the requisite experience” for running the CDER, remarked Jonathan Howard. “She’s never run a clinical trial. She is not versed in leading a sizeable institution. She is not an expert in drug approvals.”

Former heads of CBER would “grasp laws and regulations and the underlying principles of medication creation”, commented Janet Woodcock. “Frankly, she doesn’t have the kind of background that prior appointees who ran the center have had.”

This division has an enormous portfolio at the agency, Woodcock stated.

“The public just focuses on the new drug program, but the generic drug division approves numerous generic drugs. There’s a biosimilars division, over-the-counter program and so forth, and each of these must be managed,” she explained. “The area you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a substantial leadership component to the role, which manages over 5,000 personnel. “It’s a enormous leadership role, if you do it right,” Woodcock added.

Agency Reaction and Contentious Programs

In response to inquiries about Dr. Høeg's credentials and whether this appointment indicates increased cooperation among FDA leaders on immunizations, a spokesperson stated that the “inquiries are based on incorrect assumptions”.

“This background is consistent with the responsibilities of her role,” the representative said, citing the months Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the agency head's controversial priority voucher program, a disputed one-day medication authorization process that allegedly worried her predecessors. “By what process are these medications being chosen for this fast-track system? Who makes the decisions?” Dr. Howard said. “There’s a lot of confidentiality happening at the agency right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards laxer oversight of most medications, aside from vaccines.”

Public Past Work on Vaccines

With immunizations, Høeg has a clearer, if concerning, history, critics observe. She authored a research paper using unverified volunteer-provided data to determine the incidence of myocarditis after Covid immunization. She advised the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccinations are more dangerous than they are.

Part of her “desired changes” for the current federal leadership included revising rules for novel immunizations and discontinuing “unnecessary” immunizations, she stated after the election on a online show. At the FDA, Dr. Høeg has allegedly proposed barring teenage boys from obtaining Covid vaccines.

“She is an complete dogmatist who commences with her beliefs and tailors the evidence to retrofit the evidence in a very disingenuous, dishonest manner,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of fellow contrarians, {like|